Back to News
Market Impact: 0.35
BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook
Source: zacks.com
Corporate EarningsAnalyst EstimatesCorporate Guidance & OutlookCompany Fundamentals
Bristol Myers beat Q3 earnings and revenue estimates, with Growth Portfolio sales and Eliquis demand driving growth. Higher IPRD charges prompted the company to cut its 2026 EPS guidance, tempering the positive results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.00
More News
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Norwegian shares surge 13% on earnings beat, guidance raise
- Alphabet’s stock has worst day in over 20 years, dragging the S&P 500 to first loss in four days
- Taiwan Stocks Heads for Correction as Global AI Selloff Deepens
- Asia stocks tumble as AI spending concerns deepen; BOJ holds rates